Phase Genomics Announces Next Generation Cytogenomics Platform to Advance Precision Diagnosis and Treatment in Reproductive Genetics and Oncology | Business

0

SEATTLE – (BUSINESS WIRE) – October 18, 2021–

Phase Genomics, Inc., a biotechnology company at the forefront of advancing next-generation sequencing (NGS) solutions for genome assembly and analysis, today announced the launch of the beta version of its new platform for next-generation cytogenomic applications in the fields of reproductive genetics and oncology.

The platform enables fast and efficient processing of samples and does not require the cultivation of living dividing cells or the extraction of high molecular weight DNA. “This is a fast and inexpensive platform that is capable of providing tremendous benefits for answering complex genomic questions that existing methods cannot fully resolve,” said Shawn Sullivan, co-founder and Technical Director of Phase Genomics. “The flexibility of this method allows us to use a low starting volume of cells from fresh and frozen material and, more specifically, paraffin-embedded tissue. We can provide a valuable collection of genetic information from a single sample without having to wait for the results of multiple tests. With our robust chemistry and the machine learning foundations of our analytical technology, our platform offers the potential to complement or replace existing technologies such as cytogenetics, FISH and CMA in solid and liquid cancers and in the reproductive health.

While the platform can be widely applied to constitutional genetics, Phase Genomics sees the immediate utility it can bring to the prenatal market. According to Sullivan, the platform may help provide answers to the study of patient populations facing infertility or unexplained recurrent miscarriages. “For example, our platform can detect cryptic rearrangements that can cause fertility problems in a couple, it can discover new structural and copy number changes essential for fetal development in non-viable or included POC tissue samples. paraffin and, most importantly, help fuel the translation of these findings into clinical tools that will remove the emotional, financial and other burdens on patients facing these heartbreaking conditions. “

Many of the same challenges exist in oncology. Unlocking and maximizing the use of genetic information contained in uncultivable and paraffin-embedded cancer samples is a unique property of the Phase Genomics platform. Phase Genomics Co-Founder and CEO Dr Ivan Liachko said: “Phase Genomics’ ultra-long range sequencing method and machine learning-based analytical platform brings together clinical researchers and, potentially , healthcare providers, with a throughput, sequencing-based method that provides actionable insights. This information provides information that can be used in the development of new diagnostic and treatment options for cancer and genetic diseases, ultimately leading to improved patient care and outcomes. “

Today’s announcement opens access to the RUO platform to the first beta participants. Phase Genomics is engaged in a number of active partnerships with research and commercial entities and presents the first results in a poster at the American Society of Human Genetics conference. The Phase Genomics platform is intended for research only and is not intended for use in diagnostic procedures. More information on the platform is available here.

Join Phase Genomics for a webinar on Tuesday, November 30 to learn more about this technology and follow Phase Genomics on Twitter for the latest news and information.

ABOUT PHASE GENOMICS

Phase Genomics applies Hi-C and other proximity ligation methods to enable chromosome-wide genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and architecture. genome. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples, as well as genome assembly and analysis software. and advanced metagenomes.

Headquartered in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to equip scientists with genomic tools that accelerate revolutionary discoveries.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211018005750/en/

CONTACT: Jessica McNellis

630-930-4667

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA WASHINGTON

INDUSTRY KEYWORD: SOFTWARE RESEARCH ONCOLOGY TECHNOLOGY UNIVERSITY GENETICS EDUCATION SCIENCE BIOTECHNOLOGY OTHER TECHNOLOGY OTHER SCIENCE HEALTH

SOURCE: Phase Genomics, Inc.

Copyright Business Wire 2021.

PUB: 18/10/2021 11:49 / DISC: 18/10/2021 11:49

http://www.businesswire.com/news/home/20211018005750/en

Copyright Business Wire 2021.



Source link

Share.

Leave A Reply